MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2023 International Congress

August 27-31, 2023. Copenhagen, Denmark.

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • The cause of death in Parkinson’s disease

    K. Kamada, K. Kino, T. Takata (Kagawa, Japan)

  • The changes in alpha-synuclein level and oscillatory activity of substantia nigra by nigral electrical stimulation

    T. Yamamoto, R. Sakakibara, T. Uchiyama, S. Kwabara (Chiba, Japan)

  • The characterization of Parkinson’s disease related nociplastic pain based on the classification system

    T. Tezuka, T. Nukariya, S. Okusa, Y. Nihei, J. Nakahara, M. Seki (Tokyo, Japan)

  • The Comorbidity and Comedication Profiles of Patients with Progressive Supranuclear Palsy in Two German, Multicenter Cohorts: A Systematic Cross-Sectional Analysis

    S. Greten, F. Wegner, O. Krause, J. Heck, GU. Höglinger, M. Klietz (Hannover, Germany)

  • The comparison of curcumin and naringenin effects on motor function in rotenone model of Parkinson’s disease

    S. Madiha (Karachi, Pakistan)

  • The comparison of vaccination rate, health impact, and confidence of COVID-19 vaccines between patients with Parkinson’s disease and healthy population: evidence from a large multicenter survey in China

    C. Han, Z. Zhao, J. Ma (Beijing, China)

  • The contribution of Brain Bank for Aging Research to pathomechanism of Parkinson’s disease

    S. Murayama, Y. Saito (Osaka, Japan)

  • The Critical Path for Parkinson’s Consortium approach to developing consensus recommendations for neuroimaging biomarkers appropriate for use in Parkinson’s disease drug development

    M. Muller, R. Comley, J. Eberling, H. Kazmi, T. Kustermann, P. Maguire, K. Marek, C. Mcginnity, M. Minchik, C. Parker, L. Passamonti, O. Rousset, D. Russell, C. Salinas, J. Seibyl, S. Sivakumaran, J. Stoessl, A. Strafella, D. Tosun-Turgut, Y. Wang, D. Stephenson, G. Pagano (Tucson, USA)

  • The crucial role of the visual system on the PISA syndrome in Parkinson’s disease

    A. Yoritaka, T. Hayashi, K. Fusegi, S. Nakayama, M. Ando, N. Hattori (Koshigaya, Saitama, Japan)

  • The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening

    C. Panteghini, C. Reale, I. Colangelo, M. Suerz, R. Cilia, R. Eleopra, B. Garavaglia, F. Invernizzi (Milano, Italy)

  • « Previous Page
  • 1
  • …
  • 161
  • 162
  • 163
  • 164
  • 165
  • …
  • 186
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley